These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 30417881)

  • 1. Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting.
    Jönsson F; Hagedorn C; Kreppel F
    J Vis Exp; 2018 Oct; (140):. PubMed ID: 30417881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capsid Engineering of Adenovirus Vectors: Overcoming Early Vector-Host Interactions for Therapy.
    Hagedorn C; Kreppel F
    Hum Gene Ther; 2017 Oct; 28(10):820-832. PubMed ID: 28854810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methods for Modification of Therapeutic Viruses.
    Hill CAP; Bau L; Carlisle R
    Methods Mol Biol; 2020; 2058():7-29. PubMed ID: 31486029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors.
    Kreppel F; Gackowski J; Schmidt E; Kochanek S
    Mol Ther; 2005 Jul; 12(1):107-17. PubMed ID: 15963926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route.
    Wang Z; Yu B; Wang B; Yan J; Feng X; Wang Z; Wang L; Zhang H; Wu H; Wu J; Kong W; Yu X
    Oncotarget; 2016 Jul; 7(30):47287-47301. PubMed ID: 27323824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells.
    Prill JM; Espenlaub S; Samen U; Engler T; Schmidt E; Vetrini F; Rosewell A; Grove N; Palmer D; Ng P; Kochanek S; Kreppel F
    Mol Ther; 2011 Jan; 19(1):83-92. PubMed ID: 20959811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and Chemical Capsid Modifications of Adenovirus Vectors to Modulate Vector-Host Interactions.
    Weklak D; Pembaur D; Koukou G; Jönsson F; Hagedorn C; Kreppel F
    Viruses; 2021 Jul; 13(7):. PubMed ID: 34372506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reductive amination as a strategy to reduce adenovirus vector promiscuity by chemical capsid modification with large polysaccharides.
    Espenlaub S; Wortmann A; Engler T; Corjon S; Kochanek S; Kreppel F
    J Gene Med; 2008 Dec; 10(12):1303-14. PubMed ID: 18837065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hexon modification to improve the activity of oncolytic adenovirus vectors against neoplastic and stromal cells in pancreatic cancer.
    Lucas T; Benihoud K; Vigant F; Schmidt CQ; Wortmann A; Bachem MG; Simmet T; Kochanek S
    PLoS One; 2015; 10(2):e0117254. PubMed ID: 25692292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of adenovirus vectors to the LRP receptor family with the high-affinity ligand RAP via combined genetic and chemical modification of the pIX capsomere.
    Corjon S; Wortmann A; Engler T; van Rooijen N; Kochanek S; Kreppel F
    Mol Ther; 2008 Nov; 16(11):1813-24. PubMed ID: 18714309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Traceless bioresponsive shielding of adenovirus hexon with HPMA copolymers maintains transduction capacity in vitro and in vivo.
    Prill JM; Subr V; Pasquarelli N; Engler T; Hoffmeister A; Kochanek S; Ulbrich K; Kreppel F
    PLoS One; 2014; 9(1):e82716. PubMed ID: 24475024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted and shielded adenovectors for cancer therapy.
    Hedley SJ; Chen J; Mountz JD; Li J; Curiel DT; Korokhov N; Kovesdi I
    Cancer Immunol Immunother; 2006 Nov; 55(11):1412-9. PubMed ID: 16612598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biophysical targeting of adenovirus vectors for gene therapy.
    Silman NJ; Fooks AR
    Curr Opin Mol Ther; 2000 Oct; 2(5):524-31. PubMed ID: 11249755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in genetic modification of adenovirus vectors for cancer treatment.
    Yamamoto Y; Nagasato M; Yoshida T; Aoki K
    Cancer Sci; 2017 May; 108(5):831-837. PubMed ID: 28266780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
    Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
    Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted adenovirus vectors.
    Mizuguchi H; Hayakawa T
    Hum Gene Ther; 2004 Nov; 15(11):1034-44. PubMed ID: 15610604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic Adenovirus Loaded with L-carnosine as Novel Strategy to Enhance the Antitumor Activity.
    Garofalo M; Iovine B; Kuryk L; Capasso C; Hirvinen M; Vitale A; Yliperttula M; Bevilacqua MA; Cerullo V
    Mol Cancer Ther; 2016 Apr; 15(4):651-60. PubMed ID: 26861248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.
    Uusi-Kerttula H; Hulin-Curtis S; Davies J; Parker AL
    Viruses; 2015 Nov; 7(11):6009-42. PubMed ID: 26610547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors.
    Kreppel F; Hagedorn C
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33670859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Targeting of Oncolytic Adenoviruses Using Bispecific Adapter Proteins.
    Niemann J; Kühnel F
    Methods Mol Biol; 2020; 2058():31-49. PubMed ID: 31486030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.